Methods of correction of hepatotoxicity in clinical practice
https://doi.org/10.17650/3034-2473-2025-2-2-34-43
Abstract
Hepatotoxicity is damage to liver cells (hepatocytes) caused by toxic substances, including drugs, chemical compounds and other xenobiotics. Symptoms range from mild discomfort to serious disorders such as fulminant liver failure.
The review examines the types and mechanisms of hepatotoxicity, diagnostic aspects and methods of hepatoprotection against the background of antitumor drug therapy.
About the Authors
Vitaly A. Ivanov
Clinic of the Bashkir State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
Vitaly Alekseevich Ivanov.
2, Shafieva St., Ufa 450083.
Adele T. Gattarova
Clinic of the Bashkir State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
2, Shafieva St., Ufa 450083.
Dina D. Sakaeva
Clinic of the Bashkir State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
2, Shafieva St., Ufa 450083.
References
1. Le Daré B., Ferron P.J., Gicquel T. [Once upon a time the hepatotoxicity… (In French)]. Med Sci (Paris) 2021;37(3): 235–41. DOI: 10.1051/medsci/2021009
2. Niyozova Sh.H. Modern opportunities for correction of hepatotoxic syndrome for polychemotherapy of solid tumors (Literature review). European Science 2019;5(47):73–9. (In Russ.). DOI: 10.24411/2410-2865-2019-10505
3. Khomeriki S.G. Pathogenetic mechanisms and morphological manifestations of medical liver damage. Eksperimentalnaya i klinicheskaya gastroenterologiya = Experimental and Clinical Gastroenterology 2011;(6):11–21. (In Russ.).
4. Vatutin M.T., Sklyannaya E.V., El-KhatibM.A. et al. Hepatotoxicity of chemotherapeutic agents: current state of the problem. Rossiiskiy onkologicheskiy zhurnal = Russian Journal of Oncology 2016;21(6): 325–33. (In Russ.). DOI: 10.18821/1028-9984-2016-21-6-325-333
5. Chaukina S.V. Clinical and pharmacological aspects of drug metabolism under the action of cytochrome P-450 CYP2D6 isoenzyme. Trudniy patsient = Difficult Patient 2007;5(14):31–3. (In Russ.).
6. Chalasani N.P., Maddur H., Russo M.W. et al.; Practice Parameters Committee of the American College of Gastroenterology. ACG clinical guideline: Diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol 2021;116(5):878–98. DOI: 10.14309/ajg.0000000000001259
7. Pimanov S.I., Makarenko E.V. Idiosyncratic drug-induced liver injury: diagnostic and treatment. Meditsinskiy sovet = Medical Council 2017;(5):100–7. (In Russ.). DOI: 10.21518/2079-701X-2017-5-100-107
8. CIOMS Working Group. Drug-induced liver injury (DILI): current status and future directions for drug development and the post-market setting. Geneva: CIOMS, 2020.
9. Tkachenko P.E., Ivashkin V.T., Mayevskaya M.V. Correction of hepatotoxicity induced by antitumor therapy. Zlokachestvenniye opukholy = Malignant tumours 2023;13(3s2–2):69–82. (In Russ.). DOI: 10.18027/2224-5057-2023-13-3s2-2-69-82
10. Kaminskaja Yu.M. The possible use of ademethionine in the practice of psychiatrists and narcologist. Meditsinskie Novosti = Medical News 2016;3:40–4. (In Russ.).
11. Mayevskaya M.V., Lunkov V. D., Geyvandova N.I. et al. Bicyclol in the treatment of patients with chronic diffuse liver diseases. Meditsinskiy sovet = Medical Council 2020;(15):78–89. (In Russ.). DOI: 10.21518/2079-701X-2020-15-78-89
12. Yu Y.N., Chen H., Li Y. Effect of bicyclol on cisplatin-induced hepatotoxicity in the hepatocarcinoma 22 tumour-bearing mice. Basic Clin Pharmacol Toxicol 2009;104(4):300–5. DOI: 10.1111/j.1742-7843.2008.00343.x
13. Ilchenko L.Yu., Okovityi S.V. Remaxol: mechanisms of action and application in real clinical practice. Part I. Arch Int Med 2016;2(28):16–21. DOI: 10.20514/2226-6704-2016-6-3-8-18
14. Konopatskova O.M., Averyanova S.V. Adjunct therapy during combination chemotherapy for colorectal cancer. Onkologiya. Zhurnal im. P.A. Hertsena = P.A. Herzen Journal of Oncology 2016;5(1):42–6. (In Russ.). DOI: 10.17116/onkolog20165142-46
15. Tkachenko P.E., Maevskaya M.V., Ivashkin V.T. Hepatotoxicity. RUSSCO practical guidelines, part 2. Zlokachestvenniye opukholy = Malignant Tumors 2024;14(3s2):83–96. (In Russ.). Available at: https://rosoncoweb.ru/standarts/RUSSCO/2024/2024-2-05.pdf
16. Okovity S.V., Raikhelson K.L., Volnukhin A.V., Kudlai D.A. Hepatoprotective properties of glycyrrhizic acid. Experimentalnaya i klinicheskaya gastroenterologiya = Experimental and Clinical Gastroenterology 2020;184(12):96–108. (In Russ.). DOI: 10.31146/1682-8658-ecg-184-12-96-108
17. Ivashkin V.T., Raikhelson K.L., Palgova L.K. et al. Drug-induced liver injury in cancer patients. Onkogematologiya = Oncohematology 2020;15(3):80–94. (In Russ.). DOI: 10.17650/1818-8346-2020-15-3-80-94
18. Novik A.V., Protsenko S.A., Balluzek M.F. et al. Immuno-mediated adverse events. Practical recommendations of RUSSCO, part 2. Zlokachestvenniye opukholy = Malignant Tumours 2024;14(3s2):250–302. (In Russ.). DOI: 10.18027/2224-5057-2024-14-3s2-2-15
19. Okovityi S.V., Raikhelson K.L., Prikhodko V.A. Combined hepatoprotective pharmacotherapy for liver disease. Experimentalnaya i klinicheskaya gastroenterologiya = Experimental and Clinical Gastroenterology 2022;203(7):5–20. (In Russ.). DOI: 10.31146/1682-8658-ecg-203-7-5-20
20. Alyeva A.A, Nikitin I.G., Arkhipov A.V. The treatment of acute chemotherapy-induced liver injury in women with breast cancer. Lechebnoye delo = Medical Business 2018;2:74–85. (In Russ.). DOI: 10.2441/2071-5315-2018-12005
21. Drogomiretskaya E.I., Trashkov A.P., Kovalenko A.L. et al. Experimental and clinical experience of Remaxol use as an escort drug for anticancer treatment. Effektivnaya farmakoterapiya = Effective Pharmacotherapy 2018;25:34–41. (In Russ.).
Review
For citations:
Ivanov V.A., Gattarova A.T., Sakaeva D.D. Methods of correction of hepatotoxicity in clinical practice. Supportive Therapy in Oncology. 2025;2(2):34-43. (In Russ.) https://doi.org/10.17650/3034-2473-2025-2-2-34-43
Views:
61
Email this article 